Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course Sacituzumab Tirumotecan plus PD-1 inhibitors as first-line therapy in elderly PD-L1 positive driver-negative advanced NSCLC
ChiCTR2600127528Phase 2Not yet recruiting
- Sponsor
- Shanghai Geriatric Medical Center
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by Shanghai Geriatric Medical Center. Primary endpoint: Objective Response Rate (ORR). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600127528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127528.